Big Pharma devising a ‘tit for tat’ strategy

August 21, 2012
Ankur Sohanpal

India’s struggle for low cost generic medicines has been ill received by big pharma companies worldwide. India in the past gave a compulsory license to Natco Pharma to produce Bayer AG’s cancer drug Nexavar. This has put companies on the alert – they have been rallying their respective governments to curb export of generics from India and Brazil. Read more here.



View Our Publications

Case Studies, Learnings and More!

View Publications


Footer Image

Get In Touch